Navigation Links
Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report
Date:8/24/2010

hase 3 study. The trial is the first prospectively designed superiority study to be conducted in CABP, a precedent-setting clinical trial design for oral antibiotics that the company believes will make a significant contribution to the field of CABP and antimicrobial clinical trial design.

Advanced Life Sciences Chief Executive Officer, Dr. Michael T. Flavin, said: "Given Restanza's demonstrated effectiveness as a broad biodefense countermeasure against such bioterror agents as anthrax, plague and tularemia, as well as its value as a potential treatment for community acquired bacterial pneumonia, we intend to pursue all opportunities to expand our relationship with the US government and seek additional funding that could help complete development of Restanza, support regulatory filings and gain FDA approval. Our recently completed special protocol assessment with the agency should also help to position Restanza favorably for government consideration. The establishment of a strategic investment firm to help fund the development of novel antibiotics to overcome bacterial resistance represents a major step forward in the U.S. government's commitment to counter bioterrorism and infectious disease."

About the HHS Report

The HHS report recommended helping small innovator companies to develop promising countermeasures that have multi-use potential, including the establishment of an independent strategic investment firm to invest in medical countermeasure development (MCMSI).  HHS would establish and sponsor an independent strategic investment firm that would partner with small innovator companies and private investors to generate novel technologies for the required medical countermeasures. Its mission would be the development of novel technologies that have the potential for sustainable commercial applications while at the same time demonstrating applicability in the medical countermeasure public health space. The first focus would
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Worldwide, Inc. (NYSE: OWW ) will host a conference call to discuss the ... Wednesday, May 5, 2010 at 10:00 a.m. EDT ( 9:00 a.m. CDT ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20070813/AQM125LOGO ) , ... A live webcast of the call can be accessed through the Orbitz Worldwide Investor Relations ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company ... Paul F. Truex , Anthera,s President and Chief Executive Officer will present ... MA on Monday, May 3, 2010 at approximately ... , , ...
Cached Medicine Technology:Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 2Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 3Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference 2
(Date:4/23/2014)... As evidence mounts showing the potential health benefits of ... people are taking supplements. And the chemical industry is ... supplements, health effects could deter growth, so the industry ... claims, according to the cover story in Chemical ... of the American Chemical Society. , Melody M. Bomgardner, ...
(Date:4/23/2014)... R.I. Parents and physicians concerned about an increase ... marijuana can breathe a sigh of relief. According to ... 20 years worth of data from states with and ... lead to increased use among adolescents. The study is ... Journal of Adolescent Health . , "Any time ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
(Date:4/22/2014)... for low-income patients may ease the financial burden ... patient health, researchers have concluded. , A study ... avoid costs associated with insurance administration can help ... and emergency room visits, according to Mark Agee, ... The researchers estimated that the major hospital in ...
(Date:4/22/2014)... The International Communication Association will hold its ... The theme of the 2014 conference will explore ... and digital society. , Featuring over 2,300 academic ... Communication scholars representing over 40 countries, the ICA ... in the world. This year,s conference features sessions ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... be GI Awards, Honored for Commitment to Patient ... ... Procter and Gamble,Pharmaceuticals (P&G) is encouraging GI and Endoscopy professionals to,recognize outstanding ... support of the Society of Gastroenterology,Nurses and Associates, Inc. (SGNA) GI Nurses ...
... The apples and apple juice you consume may have ... in the body in the colon. New ... apple juice components actually enhance biological mechanisms that produce ... Using human fecal matter as the test substance, German ...
... MD: Artemisinins in Malaria Therapy, written by WRAIR researchers Dr. ... J. Weina (Division of Experimental Therapeutics at the WRAIR, Silver ... and recent developments in the treatment of one of the ... mankind malaria. , WRAIR, initially known as the Army ...
... Vitamin Stix Drink Mix, BROOKLYN, N.Y., March 26 ... your vitamins, 4C Totally Light2Go(TM) Vitamin Stix!,Packed with vitamins ... quickly becoming a staple for the gal on the ... three flavors of the 4C,Totally Light2Go(TM) Vitamin Stix have ...
... Increase of 126% ... -, - Removal of the Going Concern Qualification by its Independent ... Public Accountants - ... March 26 XELR8 Holdings, Inc. (Amex:,BZI), a provider of functional foods, beverages and nutritional,supplements, today ...
... SHANGHAI, China, March 26 /Xinhua-PRNewswire-FirstCall/ -- ... a leading developer,manufacturer and distributor of ... that its wholly owned subsidiary Shanghai ... an agreement with Shanghai,Disinfection Association (SDA), ...
Cached Medicine News:Health News:Nationwide Awards Recognize Nurses, Associates and Nursing Teams That Specialize in Gastroenterology and Endoscopy 2Health News:Nationwide Awards Recognize Nurses, Associates and Nursing Teams That Specialize in Gastroenterology and Endoscopy 3Health News:WRAIR investigators pioneering work on an exciting new class of antimalarial compounds 2Health News:Flavor and Vitamins on the Go 2Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 2Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 3Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 4Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 5Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 6Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 7Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 8Health News:Shanghai Disinfection Association and Linkwell Corporation Co-Establish the 'Shanghai Disinfection Association Laboratory Center' 2Health News:Shanghai Disinfection Association and Linkwell Corporation Co-Establish the 'Shanghai Disinfection Association Laboratory Center' 3
MedLook 3.0 is a medical billing software....
Managed care is a billing and tracking system....
... billing program dealing with the clerical aspects ... standard Health Insurance Claim Form, or CMS-1500. ... the internet. This means that you can ... home or work without using a web ...
... is a medical practice management ... tools and interfaces. This medical ... scheduling, patient demographics, insurance company ... paper and electronic claims filing ...
Medicine Products: